×
About 12,808 results

ALLMedicine™ Osteosarcoma Center

Research & Reviews  4,572 results

Characterization of Cell-free DNA Size Distribution in Osteosarcoma Patients.
https://doi.org/10.1158/1078-0432.CCR-22-2912
Clinical Cancer Research : an Official Journal of the Ame... Udomruk S, Phanphaisarn A et. al.

Feb 4th, 2023 - Cell-free DNA analysis is a powerful tool for non-invasively predicting patient outcomes. We analyzed the size distribution of cfDNA and assessed its prognostic and diagnostic values in an osteosarcoma cohort. The fragment size distribution and le...

A classification system of joint-salvage tumor resection in osteosarcoma of the knee: A...
https://doi.org/10.1016/j.knee.2023.01.011
The Knee; Chen G, Li M et. al.

Feb 3rd, 2023 - Joint-preserving surgery is possible for patients with juxta-articular osteosarcoma of the knee, even when the tumor invades the epiphysis. Oncologic and functional outcomes may vary due to the extent of tumor invasion, the amount of epiphysis pre...

Osteosarcoma Maintenance Therapy With OST31-164
https://clinicaltrials.gov/ct2/show/NCT04974008

Feb 2nd, 2023 - This is a Phase 2, open-label, multicenter, single-arm study in patients (12-39 years) with a recent history of pulmonary recurrent osteosarcoma that has been completely resected. Planned enrollment is a maximum of 45 patients who will receive OST...

A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
https://clinicaltrials.gov/ct2/show/NCT04833582

Feb 1st, 2023 - This is a phase 1/2 dose escalation and dose expansion study, evaluating the clinical activity and safety, pharmacodynamics, and pharmacokinetics of ZN-c3 in combination with gemcitabine in relapsed or refractory osteosarcoma.

AIMS Cancer Outcomes Study
https://clinicaltrials.gov/ct2/show/NCT04495790

Feb 1st, 2023 - It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CAM) therapy or practice. A smaller percentage of...

see more →

Guidelines  4 results

Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Li...
https://doi.org/10.1016/j.otsr.2018.12.015
Orthopaedics & Traumatology, Surgery & Research : OTSR; Gomez-Brouchet A, Mascard E et. al.

Apr 10th, 2019 - Standardized reports are essential to meeting the bone sarcoma reference center certification requirements of the French National Cancer Institute (INCa). The usual classifications of the Musculoskeletal Tumor Society (MSTS), the American Joint Co...

ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas.
https://doi.org/10.1093/annonc/mdu153
Annals of Oncology : Official Journal of the European Soc... Wilhelm M, Dirksen U et. al.

Jun 26th, 2014 - Teenagers and young adults (TYA) cancer contributes substantially to morbidity and mortality in a population with much to offer society. TYA place distinct challenges upon cancer care services, many reporting feeling marginalized and their needs n...

Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
https://doi.org/10.1093/annonc/mdn102
Annals of Oncology : Official Journal of the European Soc... Bielack S, Carrle D et. al.

May 9th, 2008 - Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Bielack S,Carrle D,Jost L, ,|diagnosis,epidemiology,pathology,therapy,therapy,diagnosis,epidemiology,pathology,therapy,

Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the ...
https://doi.org/10.1002/pbc.21596
Pediatric Blood & Cancer; Meyer JS, Nadel HR et. al.

May 6th, 2008 - The Children's Oncology Group (COG) is a multi-institutional cooperative group dedicated to childhood cancer research that has helped to increase the survival of children with cancer through clinical trials. These clinical trials include a standar...

see more →

Drugs  42 results see all →

Clinicaltrials.gov  258 results

Osteosarcoma Maintenance Therapy With OST31-164
https://clinicaltrials.gov/ct2/show/NCT04974008

Feb 2nd, 2023 - This is a Phase 2, open-label, multicenter, single-arm study in patients (12-39 years) with a recent history of pulmonary recurrent osteosarcoma that has been completely resected. Planned enrollment is a maximum of 45 patients who will receive OST...

AIMS Cancer Outcomes Study
https://clinicaltrials.gov/ct2/show/NCT04495790

Feb 1st, 2023 - It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CAM) therapy or practice. A smaller percentage of...

A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
https://clinicaltrials.gov/ct2/show/NCT04833582

Feb 1st, 2023 - This is a phase 1/2 dose escalation and dose expansion study, evaluating the clinical activity and safety, pharmacodynamics, and pharmacokinetics of ZN-c3 in combination with gemcitabine in relapsed or refractory osteosarcoma.

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02107963

Feb 1st, 2023 - Background GD2 is a well-characterized tumor antigen in neuroblastoma, which is also expressed on osteosarcomas and some other sarcomas. T cells expressing 1st generation anti-GD2 chimeric antigen receptors (CARs) were safe and mediated modest ant...

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
https://clinicaltrials.gov/ct2/show/NCT04851119

Jan 31st, 2023 - PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of tegavivint administered as an intravenous (IV) infusion over 4 hours, once weekly for 3 weeks, followed by a 1 week rest, in a 28-day cyc...

see more →

News  214 results

MDM2 Inhibitor Breaks Through in Trial of Liposarcoma, Other Advanced Malignancies
https://www.medpagetoday.com/hematologyoncology/othercancers/102805

Jan 26th, 2023 - Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral murine double minute-2 (MDM2) inhibitor milademeta...

FDA Approval Insights: Sodium Thiosulfate in Cisplatin-Treated Pediatric Solid Tumors
https://www.onclive.com/view/fda-approval-insights-sodium-thiosulfate-in-cisplatin-treated-pediatric-solid-tumors

Oct 24th, 2022 - Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and ...

Pedmark Reduces Ototoxicity Risk in Cisplatin-Treated Pediatric Solid Tumors
https://www.onclive.com/view/pedmark-reduces-ototoxicity-risk-in-cisplatin-treated-pediatric-solid-tumors

Oct 19th, 2022 - Sodium thiosulfate (Pedmark) has shown promise as an ototoxicity-mediating agent in pediatric patients with solid tumors treated with cisplatin, according to Nilay Shah, MD. He noted that additional research is needed to determine the long-term ef...

Dinutuximab Plus GM-CSF Does Not Improve DCR in Recurrent Osteosarcoma
https://www.onclive.com/view/dinutuximab-plus-gm-csf-does-not-improve-dcr-in-recurrent-osteosarcoma

Oct 14th, 2022 - The combination of dinutuximab (Unituxin) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) did not improve disease control rate (DCR) vs historical standards in patients with recurrent pulmonary osteosarcoma in complete surgical remi...

FDA Approves Pedmark for Prevention of Platinum-Induced Ototoxicity in Pediatric Solid Tumors
https://www.onclive.com/view/fda-approves-pedmark-for-prevention-of-platinum-induced-ototoxicity-in-pediatric-solid-tumors

Sep 20th, 2022 - The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors.1 The efficacy of the product was examined in pe...

see more →

Patient Education  33 results see all →